- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06512883
Kokeilu benralitsumabin tutkimiseksi lapsilla, joilla on eosinofiilisiä sairauksia (CLIPS)
Vaihe 3, avoin tutkimus benralitsumabin turvallisuuden, farmakokinetiikan ja tehon arvioimiseksi lapsilla, joilla on eosinofiilisiä sairauksia (CLIPS)
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.
Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.
Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.
The study consists of 3 periods:
- Screening period: 1 to 4 weeks
- Open-label treatment period: 52 weeks
- Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)
All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.
All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: AstraZeneca Clinical Study Information Center
- Puhelinnumero: 1-877-240-9479
- Sähköposti: information.center@astrazeneca.com
Opiskelupaikat
-
-
-
Rotterdam, Alankomaat, 3015 GD
- Rekrytointi
- Research Site
-
-
-
-
-
São Paulo, Brasilia, 01232-010
- Rekrytointi
- Research Site
-
-
-
-
-
Ahmedabad, Intia, 380052
- Rekrytointi
- Research Site
-
-
-
-
-
Petah Tikva, Israel, 49202
- Rekrytointi
- Research Site
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G1X8
- Rekrytointi
- Research Site
-
-
-
-
-
Guadalajara, Meksiko, 44620
- Rekrytointi
- Research Site
-
-
-
-
-
Kielce, Puola, 25-734
- Rekrytointi
- Research Site
-
Warsaw, Puola, 04-730
- Ei vielä rekrytointia
- Research Site
-
-
-
-
-
Lille, Ranska, 59037
- Rekrytointi
- Research Site
-
Montpellier, Ranska, 34295
- Keskeytetty
- Research Site
-
-
-
-
-
Altındağ, Turkki (Türkiye), 06230
- Rekrytointi
- Research Site
-
Istanbul, Turkki (Türkiye), 34093
- Rekrytointi
- Research Site
-
-
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Rekrytointi
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45229
- Rekrytointi
- Research Site
-
Highland Hills, Ohio, Yhdysvallat, 44106-2624
- Rekrytointi
- Research Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
All Cohorts:
- Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
- Body weight greater than (>=) 15 kilograms (kg).
EGPA Cohort:
- Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
- Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).
HES Cohort:
- Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
- Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
- AEC ≥1000 cells/µL at screening (Visit 1).
- Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.
Exclusion Criteria:
All Cohorts:
- Any current malignancy or history of malignancy.
- History of anaphylaxis to any biologic therapy or vaccine.
- Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
- Previous receipt of benralizumab in an interventional clinical study.
EGPA Cohort:
- Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
- EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
- Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.
HES Cohort:
- Life-threatening HES or HES complications, as judged by the investigator.
- Hypereosinophilia of unknown significance (HE-US).
- Diagnosis of systemic mastocytosis.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: EGPA/HES Cohort: Benralizumab
Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period. |
Benralizumab will be administered as SC injection on Q4W.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Aikaikkuna: From screening (Week -4 to -1) until Week 52
|
The safety and tolerability of benralizumab will be evaluated. |
From screening (Week -4 to -1) until Week 52
|
|
Serum Concentrations of Benralizumab
Aikaikkuna: Weeks 0, 12, 24, 25, 36, and 52
|
The PK of benralizumab will be evaluated. |
Weeks 0, 12, 24, 25, 36, and 52
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
EGPA Cohort: Percentage of Participants with Remission at Week 24
Aikaikkuna: At Week 24
|
Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day. |
At Week 24
|
|
Number of Participants with Positive Antidrug Antibody (ADA)
Aikaikkuna: Weeks 0, 12, 24, 36, 48, and 52
|
The immunogenicity of benralizumab will be evaluated. |
Weeks 0, 12, 24, 36, 48, and 52
|
|
Change From Baseline in Peripheral Blood Eosinophil Count
Aikaikkuna: From Baseline to Weeks 0, 12, 24, 36, 52
|
The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated. |
From Baseline to Weeks 0, 12, 24, 36, 52
|
|
EGPA Cohort: Time to First EGPA Relapse
Aikaikkuna: Up to 52 weeks
|
The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening. |
Up to 52 weeks
|
|
HES Cohort: Time to first HES worsening/flare
Aikaikkuna: Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Percentage of participants who experience a HES worsening/flare
Aikaikkuna: Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Number of HES worsening/flares (annualised rate/year)
Aikaikkuna: Up to 52 weeks
|
The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows: The total number of flares *365.25 / total duration of follow-up in the treatment period (days). |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
Aikaikkuna: Up to 52 weeks
|
The effect of benralizumab on corticosteroid use will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Time to first haematologic relapse
Aikaikkuna: Up to 52 weeks
|
The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL. |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants with haematologic relapse
Aikaikkuna: Up to 52 weeks
|
The effect of benralizumab on haematologic measures of disease activity will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
Aikaikkuna: Up to 52 weeks
|
The effect of benralizumab on haematologic measures of disease activity will be evaluated. |
Up to 52 weeks
|
|
HES Cohort: Patient Global Impression of Change (PGI-C) Score
Aikaikkuna: Weeks 12, 24, 36 and 48
|
The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse'). |
Weeks 12, 24, 36 and 48
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Verisuonisairaudet
- Sydän-ja verisuonitaudit
- Autoimmuunisairaudet
- Immuunijärjestelmän sairaudet
- Ihosairaudet
- Lymfaattiset sairaudet
- Lymfoproliferatiiviset häiriöt
- Ihotaudit, verisuonisairaudet
- Vaskuliitti
- Anti-neutrofiilien sytoplasmisiin vasta-aineisiin liittyvä vaskuliitti
- Granulooma
- Systeeminen vaskuliitti
- Iho- ja sidekudostaudit
- Hemic- ja imusuutteet
- Churg-Straussin oireyhtymä
- benralitsumabi
Muut tutkimustunnusnumerot
- D3255C00004
- 2023-508533-14-00 (Muu tunniste: EU CT)
- EMEA-001214-PIP09-21-M02(EGPA) (Muu tunniste: Paediatric Investigational Plan Number)
- EMEA-001214-PIP04-19-M02 (HES) (Muu tunniste: Paediatric Investigational Plan Number)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-jaon aikakehys
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-jaon käyttöoikeuskriteerit
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .